source
- Compass Pathways CEO says company will proceed cautiously as it readies psychedelic therapy for FDA reviewCompass Pathways chief executive Kabir Nath told reporters at the STAT Summit that the company will "go slow before we go fast," emphasizing that early negative experiences could hurt the emerging…
- FDA issues warning letters to manufacturers over CGMP and GLP violationsThe U.S. Food and Drug Administration has sent warning letters to multiple drug manufacturers for failing to meet current good manufacturing practice requirements. The agency highlighted problems e…